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Abstract
Background: The incidence and severity of dengue in Latin America has increased substantially in recent decades and data
from Puerto Rico suggests an increase in severe cases. Successful clinical management of severe dengue requires early
recognition and supportive care.
Methods: Fatal cases were identified among suspected dengue cases reported to two disease surveillance systems and
from death certificates. To be included, fatal cases had to have specimen submitted for dengue diagnostic testing including
nucleic acid amplification for dengue virus (DENV) in serum or tissue, immunohistochemical testing of tissue, and
immunoassay detection of anti-DENV IgM from serum. Medical records from laboratory-positive dengue fatal case-patients
were reviewed to identify possible determinants for death.
Results: Among 10,576 reported dengue cases, 40 suspect fatal cases were identified, of which 11 were laboratory-positive,
14 were laboratory-negative, and 15 laboratory-indeterminate. The median age of laboratory-positive case-patients was 26
years (range 5 months to 78 years), including five children aged ,15 years; 7 sought medical care at least once prior to
hospital admission, 9 were admitted to hospital and 2 died upon arrival. The nine hospitalized case-patients stayed a mean
of 15 hours (range: 3–48 hours) in the emergency department (ED) before inpatient admission. Five of the nine case-
patients received intravenous methylprednisolone and four received non-isotonic saline while in shock. Eight case-patients
died in the hospital; five had their terminal event on the inpatient ward and six died during a weekend. Dengue was listed
on the death certificate in only 5 instances.
Conclusions: During a dengue epidemic in an endemic area, none of the 11 laboratory-positive case-patients who died
were managed according to current WHO Guidelines. Management issues identified in this case-series included failure to
recognize warning signs for severe dengue and shock, prolonged ED stays, and infrequent patient monitoring.
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Introduction
Dengue is a major public health problem throughout the tropics
and subtropics [1]. During the last decade, both the incidence and
severity of dengue in Central and South America, Mexico, and the
Caribbean have increased substantially [2]. In Puerto Rico, dengue
virus (DENV) was first isolated during a large epidemic in 1963 [3].
Since then, there have been several large island-wide epidemics of
dengue with dengue hemorrhagic fever (DHF), including two
epidemics in 1998 and 2007 that involved the simultaneous
transmission of all four DENV [4,5]. Despite the well-publicized
island-wide epidemic in 2007 and an increasing trend in severe
disease [5], the true incidence of fatal dengue is likely under-
estimated because of underreporting and under-recognition [6,7],
which has included failure to designate dengue as an underlying
cause of death on death certificates [8].
Primary prevention of dengue through vector control activities
has had limited success worldwide [9]. Currently, no vaccine exists
to prevent dengue nor is there an anti-viral treatment. However,
secondary prevention to reduce mortality through improved
clinical case management has substantially lowered the mortality
rate for severe dengue from 10–20% to ,1% in some countries
over the past two decades [10,11]. To begin to understand patient
care and management issues related to dengue associated deaths
including under-recognition of severe dengue, we performed a
review of medical records from the case-series of all laboratory-
positive fatal cases in Puerto Rico that occurred during the 2007
epidemic.
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Data sources
Suspected deaths due to dengue with onset of illness in 2007
were identified from three sources: 1) the passive dengue
surveillance system (PDSS) maintained by the Puerto Rico
Department of Health (PRDH) and Centers for Disease Control
and Prevention (CDC) Dengue Branch, 2) death certificates filed
at the Demographic Registry of Puerto Rico, and 3) hospital-based
infection control nurse dengue surveillance system (ICNDSS) as
previously described [4,6]. Complete medical records from all
hospitalizations, emergency room and clinic visits for suspected
dengue deaths were obtained and reviewed by physician
investigators using a standardized instrument to collect demo-
graphic, clinical, and laboratory data. This project underwent
institutional review at the CDC and it was determined not to be
subject to formal institutional review board review requirements as
defined by US regulations (i.e., Title 45 Code of Federal
Regulations Part 46).
Suspected dengue cases are reported to PDSS by health care
providers who submit a serum specimen for diagnostic testing
accompanied by a Dengue Case Investigation Report (DCIR). For
fatal cases, autopsy tissue is occasionally sent with the serum
specimen and DCIR. The DCIR includes patient demographic,
clinical, travel, vaccination, and disease outcome data including
whether the illness resulted in hospitalization, death or both.
DCIR data are entered into an electronic data base. Deaths
reported to PDSS are immediately confirmed by calling the
reporting hospital.
Hospitalized suspected dengue cases are reported to the
ICNDSS by nurse epidemiologists or infection control nurses.
Because of a steady decline in participation, data from this
reporting system are only used to augment PDSS data. When an
ICNDSS case report indicated a patient death these cases were
confirmed and investigated.
Death certificates with ‘‘dengue’’ included as a cause or
contributing factor in the death were obtained on a monthly
basis. The PDSS database was queried to determine if a diagnostic
specimen was received for the case.
Laboratory testing
All serum specimens were tested by DENV serotype-specific, real-
time, reverse transcriptase polymerase chain reaction (RT-PCR)
[12,13]. Specimens were also tested for anti-DENV IgM with an
IgM antibody-capture enzyme-linked immunosorbent assay (MAC-
ELISA) [14].Specimenswith borderlineresults were retestedagainst
a standard negative serum. A quantitative IgG ELISA was per-
formed to detect anti-DENV IgG in all specimens [15]. As human
West Nile virus (WNV) infections were identified for the first time in
PuertoRico inearly2007(i.e.,among healthyblood donors), [16] all
fatal cases were tested by anti-WNV MAC-ELISA and if positive,
WNV specific RT-PCR [17] and plaque reduction neutralization
test (PRNT90) assays were performed to differentiate between
DENV and WNV infections [18].
All serum specimens with sufficient volume remaining after
dengue diagnostic testing was completed were also screened for
IgM antibodies to Leptospira at the CDC Bacterial Zoonoses
Branch, Zoonoses and Select Agent Laboratory using the rapid
dipstick ELISA ImmunoDOT kit (GenBio, Inc., San Diego, CA).
Specimens with positive or borderline ELISA results were further
tested using the microscopic agglutination test (MAT) using 20
Leptospira reference antigens representing 17 serogroups [19].
Autopsy tissue was sent to CDC Infectious Diseases Pathology
Branch for identification of DENV antigen by immunohistochem-
ical (IHC) microscopy and DENV-specific RT-PCR. If micro-
scopic examination of the tissue or the clinical history was
suggestive of leptospirosis (e.g., interstitial nephritis, pulmonary
hemorrhage), IHC microscopy was conducted using 16 polyclonal
anti-Leptospira spp. antibodies. Depending on the clinical presen-
tation and histopathology of the tissue specimens submitted,
additional testing with histochemical stains, immunohistochemis-
try, and/or additional molecular assays was performed to
determine the infecting pathogen.
Definitions
A suspected dengue case is a dengue-like, acute febrile illness in a
person with that clinical diagnosis and a specimen submitted for
dengue diagnostic testing. A laboratory-positive dengue case is a
suspected dengue case with any of the following: (1) detection of
DENV RNA in serum, cerebrospinal fluid, or tissue by RT-PCR;
(2) identification of DENV antigen in tissue by IHC assay; (3) IgM
anti-DENV seroconversion or demonstration of a fourfold or
greater increase in anti-DENV IgG titers in paired serum
specimens; or (4) positive anti-DENV IgM in a single serum
specimen. A laboratory-negative dengue case is a suspected dengue case
for which no anti-DENV IgM is detected in a serum specimen
collected .5 days after fever onset (i.e., a negative convalescent
phase specimen), and no anti-DENV IgM, DENV RNA or DENV
antigen is detected from serum collected #5 days after onset (i.e. a
negative acute phase specimen) or tissue (if submitted). Labora-
tory-negative dengue cases are hence considered to have the
diagnosis of dengue ‘ruled out’. A laboratory-indeterminate dengue case is
a suspected dengue case that subsequently had no DENV RNA or
anti-DENV IgM detected in specimen collected #5 days after
fever onset, and no convalescent specimen submitted for
diagnostic testing.
A laboratory-confirmed leptospirosis case is a suspected dengue
case with any of the following laboratory results: 1) isolation of
Leptospira from a clinical specimen, 2) fourfold or greater increase
in MAT titer between acute- and convalescent-phase serum
specimens studied at the same laboratory, 3) demonstration of
Leptospira in tissue by immunohistochemistry, or 4) MAT titer
$800 in a serum specimen. A presumptive leptospirosis case is a
suspected dengue case with any of the following laboratory results:
1) presence of MAT titer .200 but ,800 in a serum specimen, or
2) demonstration of Leptospira in a clinical specimen by darkfield
microscopy.
Author Summary
Dengue is a major public health problem in the tropics and
subtropics; an estimated 50 million cases occur annually
and 40 percent of the world’s population lives in areas
with dengue virus (DENV) transmission. Dengue has a wide
range of clinical presentations from an undifferentiated
acute febrile illness, classic dengue fever, to severe dengue
(i.e., dengue hemorrhagic fever or dengue shock syn-
drome). About 5% of patients develop severe dengue,
which is more common with second or subsequent
infections. No vaccines are available to prevent dengue,
and there are no specific antiviral treatments for patients
with dengue. However, early recognition of shock and
intensive supportive therapy can reduce risk of death from
,10% to less than 1% among severe dengue cases.
Reviewing dengue deaths is one means to identify issues
in clinical management. These findings can be used to
develop healthcare provider education to minimize
dengue morbidity and mortality.
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course that resulted in the need for cardiopulmonary resuscitation
(e.g., a hypoxic seizure, an intracranial bleed).
A hemorrhagic manifestation is defined by the presence of any of the
following: petechiae, purpura, ecchymosis, epistaxis, gingival
bleeding, hematuria, menorrhagia, hemoptysis, hematemesis,
melena, or an intracranial bleed.
Dengue fever (DF) is any suspected dengue case that meets the
1997 World Health Organization (WHO) case definition [20],
which include acute onset of fever plus two or more of the
following sign or symptoms: headache, retro-orbital pain, myalgia,
arthralgia, rash, hemorrhagic manifestation, and leucopenia.
Leucopenia was defined by white cell count ,5.0610
9/L.
Dengue hemorrhagic fever (DHF) is any suspected dengue case that
meets the following WHO criteria [20]: (1) fever or recent history
of fever, (2) any hemorrhagic manifestation, (3) platelet count of
#100,000/mm
3, and (4) evidence of increased vascular perme-
ability and plasma leakage which includes: (a) hemoconcentration
with a hematocrit $20% above the U.S. population mean for age
and sex, [21,22] (b) $20% decline in hematocrit following
volume-replacement treatment compared to baseline, (c) presence
of pleural effusion or ascites detected by any imaging method, or
(d) a serum protein or albumin ,2.5 percentile for age and sex
[23–25].
Dengue shock syndrome (DSS) is any case that meets the four criteria
for DHF and has evidence of circulatory failure manifested by (1)
rapid and weak pulse and narrow pulse pressure (#20 mmHg
[2.7 kPa]) or (2) hypotension for age and cold, clammy skin and
restlessness.
A primary DENV infection (first DENV infection) is a laboratory-
positive case in which the anti-DENV IgG titer was ,1:160 in an
acute serum specimen collected #5 days after the onset of
symptoms [14].
A secondary DENV infection ($second DENV infection) is a
laboratory-positive case in which the anti-DENV IgG titer was
$1:160 in an acute serum specimen [14].
Results
A total of 10,576 suspected dengue cases were reported with
onset of symptoms in 2007; 10,171 to the PDSS only, 68 to the
ICNDSS only, and 337 to both systems. There were 40 suspected
dengue deaths reported to these surveillance systems and 4
additional deaths were identified only by the Demographic
Registry of Puerto Rico. These latter fatal cases had no diag-
nostic testing performed and are not considered further in this
report.
Of the 40 suspected dengue deaths, one case-patient had both
tissue and paired serum specimens submitted, eight had tissue and
acute serum, two had tissue and convalescent serum, four had
tissue alone, one had paired serum specimens, five had only a
convalescent serum specimen, and 19 had only an acute serum
specimen. Eleven of the 40 suspected deaths were laboratory-
positive dengue cases (Table 1); a 0.6% case-fatality rate among
the 1,776 hospitalized laboratory-positive dengue cases reported to
PDSS. There were no co-infections identified. Of the remaining
29 deaths, 14 were laboratory-negative cases; nine had leptospi-
rosis (three confirmed cases and six presumptive cases) and one
had group A Streptococcus detected by tissue IHC. Fifteen deaths
were laboratory-indeterminate cases although three met WHO
clinical criteria for DHF with gastrointestinal hemorrhage and
four met criteria for DF with thrombocytopenia and a hemor-
rhagic manifestation, but had no evidence of plasma leakage
documented in the medical records.
Description of laboratory-positive deaths
Of the 11 laboratory-positive case-patients who died, eight were
DENV RT-PCR positive in tissue, serum or both, and three were
anti-DENV IgM positive in a single serum specimen (Table 1). Of
the five DENV RT-PCR positive in serum, three were DENV-3,
one was DENV-2, and one was DENV-1. Among the six case-
patients with an acute serum specimen, four had secondary
infections and two had primary infections. In the four laboratory-
positive case-patients with tissue specimens, DENV was identified
by IHC or RT-PCR in lung, liver and kidney specimens, and the
most common histopathologic findings were intraalveolar edema
and hemorrhage; congestion in the spleen, liver, and/or kidney;
and fatty metamorphosis of the liver.
The median age of laboratory-positive case-patients was 26
years (range: 5 months to 78 years). Five were aged ,15 years,
four were 20–45 years, and two were .70 years. Seven were male.
Five of six adults had at least one co-morbidity: two had asthma;
one had an autoimmune hypothyroid disease; one had Type 2
diabetes mellitus (DM II) and hypertension; and one had DM II,
chronic anemia, congestive heart failure, chronic obstructive
pulmonary disease, and hypertension. In addition, four adults
were overweight (i.e., body mass index [BMI] of 25.0–29.9), and
one adult and one child were obese (i.e., BMI $30.0 or a BMI for
age .95%).
Opportunities for early diagnosis and intervention
Seven of the 11 case-patients sought medical care at least once
prior to first hospital admission or presenting dead on arrival
(DOA) to an emergency department (ED); three were seen by a
clinician more than once but only 1 was diagnosed with a
‘‘dengue-like-syndrome’’. Instead, the most common diagnoses
given at these outpatient visits were upper respiratory infection
with pharyngitis and/or cough, followed by acute gastroenteritis
and viral syndrome. None of the seven case-patients had
specimens submitted for dengue diagnostic testing until hospital-
ization (median 5 days post fever onset; range: 3–9 days) even
though they saw clinicians early in the clinical course (median 2
days post fever onset; range 1–5 days). In addition, three case-
patients had one or more warning signs for severe dengue at the
time of fever defervescence, including persistent vomiting, severe
abdominal pain, and narrow pulse pressure, and were sent home.
A fourth case-patient, diagnosed with an upper respiratory tract
infection as an outpatient, had a seizure at home the day after first
being seen as an outpatient and died on the way to the hospital.
Upon final presentation to an ED, the 11 laboratory-positive
case-patients had been sick a median of 4 days (range: 1–7 days).
Two case-patients presented DOA and four were afebrile, three of
which, had signs of shock. A seventh case-patient became afebrile
while in ED and developed tachycardia, delayed capillary refill,
and a narrow pulse pressure. Six case-patients had warning signs
for severe dengue upon arrival to the ED including persistent
vomiting (5/9) and abdominal pain (4/9). However, five of the
nine case-patients were given a low (least severe) or intermediate
severity triage score.
Nine case-patients were admitted to a hospital after a mean ED
stay of 15 hours (median 12 hours, range: 3–48 hours) (Table 2).
Initial complete blood count done in ED found that six case-
patients had platelet counts ,100,000/mm
3 (median 78,000;
range 8,000–410,000), five were leukopenic, two were hemocon-
centrated (hematocrit 20% above mean for age/sex) and two had
a hematocrit ,2.5% for age and sex. Six of the nine case-patients
met criteria for DF and three met criteria for DHF/DSS. Five
case-patients had ‘‘dengue’’ listed in the admission differential
diagnosis.
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www.plosntds.org 5 April 2012 | Volume 6 | Issue 4 | e1614During their hospital stay, several case-patients developed
warning signs for severe dengue including persistent vomiting
(1/9), abdominal pain (1/9), restlessness (4/9), and mental status
changes (4/9). In six cases, warning signs were not recognized as
such as there were no new orders or change in the clinical
management.
In the end, six of the 11 laboratory-confirmed fatal cases met
criteria for DHF or DSS as determined throughout their clinical
course and at autopsy (Table 3). Ten of the 11 case-patients had at
least 1 hemorrhagic manifestation and nine case-patients had
evidence of plasma leakage. Nine of 11 had thrombocytopenia
documented.
Monitoring and level of care
Of the nine laboratory-positive case-patients admitted to a
hospital, only three had capillary refill time assessed in the ED or
at admission. Vital signs were measured at a median of every
3 hours in the ED but most case-patients had less frequent
measurements after admission (Table 2). Two case-patients were
admitted from the ED to the ICU and had vital signs measured
every 1 or 2 hours.
Eight of nine hospitalized case-patients died during hospitaliza-
tion, and the other case-patient was found dead at home within
18 hours of hospital discharge (Table 3). Three of the eight case-
patients who died in the hospital had no recorded blood pressure
measurements during the 8 hours before their terminal event. Five
case-patients had their terminal event on the inpatient ward and
another case-patient was transferred to ICU and had a terminal
event within minutes of the transfer. Of those who died in hospital,
six of eight case-patients died during a weekend (between 1701 on
Friday and 0759 Monday), and five had a terminal event between
2300 and 0759.
Interventions and supportive care
All nine hospitalized case-patients received intravenous fluids,
most commonly 0.9% normal saline (Table 2). Four received
0.45% normal saline while in shock. Four received intravenous
albumin (5% or 25% solution) during their hospitalization but only
one received colloids prior to the terminal event. Three of the nine
hospitalized case-patients had signs of fluid overload prior to death
including periorbital edema, dyspnea, and abdominal distention
documented in their medical record.
There was frequent use of corticosteroids in laboratory-positive
case-patients (Table 2). Five of the nine hospitalized case-patients
received intravenous methylprednisolone as inpatients and one
received dexamethasone in the ED before hospital admission. One
case-patient who was DOA received oral prednisone during an
outpatient visit.
Hematocrit levels were assessed every 17 hours on average
(range 10–42 hours) for the six hospitalized case-patients with
clinically significant hemorrhage (Table 2 and 3). Three of these
six case-patients were given packed red blood cells; two in response
to frank blood per nasogastric tube or rectum and one during the
final code. One of these case-patients also received fresh frozen
plasma in response to clinically significant bleeding. No case-
patients were given whole blood. Two of the case-patients who
received packed red blood cells also received platelets; one in
response to clinically significant bleeding and one during the final
code. Four additional case-patients had platelets ordered but they
did not receive them prior to death.
Complications and reported causes of death
Many of the nine hospitalized case-patients developed compli-
cations including metabolic acidosis (6/9), prolonged shock (6/9),
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www.plosntds.org 6 April 2012 | Volume 6 | Issue 4 | e1614acute respiratory failure (6/9), fluid overload (3/9), and seizures
(3/9) (Table 2). Only 1 of the 11 case-patients had evidence of a
secondary bacterial infection even though most patients had blood
and urine cultures taken. Dengue, DHF, DSS, or status-post
dengue syndrome was listed as the cause of death or a contributing
factor in only five case-patients. The remaining six death
certificates listed causes or contributing factors including hypovo-
lemic shock, hypotension, metabolic acidosis, septicemia unspec-
ified, bronchopneumonia unspecified, viral infection unspecified,
brain death, and ischemic cerebral infarct.
Discussion
This case review showed that although there was a relatively low
case-fatality rate among hospitalized patients with dengue during the
2007 epidemic in Puerto Rico, the clinical management of all fatal
dengue cases deviated from the current WHO guidelines. Although
chronic disease and bacteremia have been associated with poor
outcomes, including death among adults with severe dengue [26–30],
only two adult case-patients had co-morbidities that may have
contributed to their deaths. In short, the majority of laboratory-
positive fatalities appeared to be due to dengue, and none of our case-
patients were managed according to the 1997 WHO Guidelines.
This review illustrates various levels of delay in receipt of
appropriate level of care. Delay in receipt of the appropriate level
ofcareand prolonged shockhasbeen associated with pooroutcomes
among patients with severe dengue [31–33]. Most of our case-
patients were seen by a clinician at least once before being
hospitalized or presenting DOA, and only one case-patient was
identified as having dengue. In fact, four of the seven case-patients
seen as outpatients could have benefited from timelier referral to an
inpatient facility including the three that sought care multiple times
but were sent home even though they had warning signs of severe
dengue and another that presented DOA the day after being seen.
Thesefindingsindicate theneed for educating patientsand clinicians
in identifying dengue and recognizing warning signs for severe
dengue so that anticipatory guidance can be given to minimize delay
and appropriate care can be initiated in a timely manner.
Poor disease recognition and failure to detect increased disease
severity in the ED appeared to contribute to the delay in receipt of
appropriate inpatient care. Contributing factors included patients
being given low triage scores and infrequent monitoring of vital
signs. Lack of inpatient beds was only documented in two cases and
probably did not contribute to poor outcomes. We are not aware of
any published studies that indicate that use of triage scores/systems
may be a factor in treatment delay for dengue as has been shown for
severe sepsis [34]. Automated triage systems detect patients with
high body temperature and low systolic blood pressure; whereas, it
would be useful in dengue endemic countries for these systems to
also identify patients with hypothermia, narrow pulse pressure and
age-specific tachycardia in the absence of hyperthermia. In
countries with a sizeable number of adult patients with severe
dengue, it would be important for triage systems to identify patients
with chronic hypertension as low- normal systolic blood pressure
may be abnormal for these patients. The early markers for severe
disease and mortality among dengue patients needs to be better
defined [28,35] and used to develop rules for triage of patients in
dengue endemic areas, especially during epidemics.
Monitoring patients closely for warning signs of severe disease
and early signs of shock until at least 24 hours after fever
defervescence is important as patients may rapidly deteriorate at
this time. Most of our case-patients were admitted to the general
inpatient ward, had infrequent monitoring of vital signs, and
hematocrit levels were not ordered at a frequency necessary to
monitor plasma leakage with its attendant hemoconcentration and
response to fluid resuscitation. In addition, we found that warning
signs and early signs of shock were not acted upon in a timely
manner even when clearly documented by the nursing staff. Many
hospital deaths occurred during the night or weekend, and a few
Table 3. Clinical Features of the Fatal Laboratory-positive Dengue Cases at Time of Death or End of Hospital Stay, 2007, Puerto
Rico.
Clinical Features of the Fatal Laboratory-positive Dengue Cases At Time of Death or End of Hospital Stay
{
Case
Met DHF
{
criteria
Lowest
PLTs610
9/L
Lowest
HCT % Hemorrhagic Manifestations Signs of Plasma Leakage
LOS triage to
terminal event
GI Pulmonary Vaginal ICH Other Effusion
Low
albumin
Hemo-
concentrated
1 No 234 46.5 No No No No Yes Pleural Yes Yes 13.0
2 Yes 53 9.2 Yes Yes No No Yes Pleural Yes Yes 83.8
3 No 28 5.9 UNK No No UNK Yes UNK UNK No DOA
4 Yes 18 20.7 Yes No No No Yes Pleural Ascites Yes No 59.2
5 Yes 50 29.5 Yes No No No Yes No Yes No 71.7
6 No 34 24.7 No No No No No Ascites Yes No Home
7 Yes 29 33.6 UNK Yes No UNK Yes Pleural Yes No 30.0
8 Yes 8 45.4 Yes No No UNK Yes Ascites Yes Yes 19.7
9 No UNK UNK No Yes No No No Pleural Ascites
Pericardial
UNK UNK DOA
10 No 61 34.5 No No No No Yes No No No 124.8
11 Yes 32 26.1 Yes No Yes Yes Yes Pleural Yes No 91.8
This table describes the clinical features of laboratory positive dengue case-patients at time of death or end of hospital stay.
{DHF=dengue hemorrhagic fever; PLT=platelet; HCT=hematocrit; GI=gastrointestinal; ICH=intracranial hemorrhage; LOS=length of stay.
{DHF criteria as defined by World Health Organization in Dengue Hemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. Second edition. Geneva: World
Health Organization.
doi:10.1371/journal.pntd.0001614.t003
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www.plosntds.org 7 April 2012 | Volume 6 | Issue 4 | e1614had no blood pressure measurement recorded for several hours
before death.
For patients with severe dengue, the mainstay of successful
management is early and judicious replacement of plasma leakage
with isotonic crystalloid solutions, including normal saline,
Ringer’s lactate, Ringer’s acetate, or 5% glucose in normal saline,
followed by colloid solutions in the event that shock is refractory
[36–38]. Our review found that some case-patients were given
intravenous non-isotonic crystalloid solutions during shock, and
only one patient was given intravenous colloid solution before the
terminal event even though six of the eight case-patients who died
in hospital had refractory shock.
Most case-patients received corticosteroids even though their
use has been shown to be no more effective than placebo or no
treatment in reducing the number of deaths and the need for
blood transfusion [39]. Two recent reviews found insufficient
evidence to justify the use of corticosteroids in managing dengue
shock syndrome and recommended that corticosteroids not be
used to treat dengue [39,40]. In addition, there is no convincing
physiological rationale for their use and there are multiple
potential side effects including stress ulceration and upper
gastrointestinal bleeding in critically ill patients, hyperglycemia,
and immunosuppression with an increased risk for infection.
Although most case-patients had clinically significant bleeding,
few received packed red blood cells and none received whole blood.
Infrequent monitoring of hematocrit and vital signs may have
contributed to the late detection of hemorrhage. Instead, complete
blood counts may have been ordered to monitor platelet counts.
Platelet transfusions were ordered for most of the hospitalized case-
patients but many died before receiving them. Guidelines generally
recommend platelet transfusions be given to patients who have
clinically significant bleeding; however, use of prophylactic platelet
transfusions for dengue is a subject of debate [41]. Recent studies
have found that in children, platelet counts are not predictive of
bleeding[32,42,43] nordotheycorrelatewith bleeding severity[44].
Instead, prolonged shock was found to be a risk factor for severe
hemorrhage [32]. In a study of 106 pediatric patients with DSS and
coagulopathy, prophylactic platelet transfusions for platelet counts
,30610
9 L
21 and fresh frozen plasma did not prevent hemorrhage
and may have contributed to the development of pulmonary edema
resulting in increased hospital stays [45]. Moreover, prophylactic
platelet transfusions do not seem to expedite platelet recovery
[45,46]. Studies among adults have conflicting results; some found
no association between a platelet count and bleeding [46], while
others found an association between platelet counts of 50610
9 L
21
or less than 20610
9 L
21 and bleeding [42,47].
Lastly, our review illustrates the difficulties in making a laboratory
diagnosis of dengue, especially late in the course of the disease. Even
though we tested acute and convalescent specimens by all available
diagnostic tests, 37.5% (15) had an indeterminate diagnosis. This
occurred because the availablespecimen(s)were incorrectlycollected
with respect to the course of dengue. Seven of the 15 case-patients
with an indeterminate dengue diagnosis had specimens obtained at
day 4 or 5 post onset of symptoms, a period when viremia or anti-
DENV IgM may be undetectable. Physicians practicing in dengue
endemic areas need to be aware of including dengue in their
differential diagnosisofacute febrileillness and that they mustobtain
serumsamplesfordiagnostictesting early(days1to3) aftersymptom
onset. To improve diagnostic accuracy for patients who present late,
samples should be collected immediately and a second collected 5 to
7 days later. Whether more sensitive diagnostic assays can be
developed to increase diagnostic accuracy for specimens collected
only during the critical period of dengue remains to be determined.
There are limitations to our study. This was a small case-series
study which only generates descriptive data and does not identify
risk factors associated with dengue deaths. The identification of risk
factors must await case-control studies in a larger number of dengue
fatalities. However, the high frequency of certain findings (e.g., use
of non-isotonic fluids for refractory shock, infrequent monitoring
vital signs, not identifying warning signs for severe dengue) suggests
that they may be risk factors for poor outcomes. The other
limitation is that our catchment systems may not have detected all
fatal dengue cases, which may have introduced biases due to
incomplete case ascertainment. However, our present surveillance
approach again confirmed that in Puerto Rico, dengue continues to
not be listed as the cause or underlying cause of death among
laboratory-confirmedfatal cases[4,8].Betterestimates ofthe degree
of under-recognition and reporting of dengue deaths must await
additional assessment ofreporting studies. However, the consistency
of issues in clinical management in our case-series suggests that
biases due to underreporting are probably minimal.
Clearly there is need to improve surveillance of severe and fatal
cases, and to evaluate clinicians’ diagnosis and clinical management
ofdengueinPuertoRico.Ourpresumptionisthat,eveninadengue
endemic area where the disease should be well known, sustained
health care provider education and training are necessary to
improve detection, diagnosis, and management of dengue and
lower dengue morbidity and mortality. CDC Dengue Branch and
PRDH in collaboration with a number of medical organizations
used findings from this fatal case review and a physician survey that
we conducted in 2007–08 (CDC data, not published) to develop a
post graduate course on the clinical management of dengue for
physicians in Puerto Rico which was implemented in 2009–10.
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